



Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference

November 30, 2022

HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- [Kiniksa Pharmaceuticals, Ltd.](https://www.kiniksa.com) (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America Securities 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 10:15 a.m. Eastern Time.

A live webcast of Kiniksa's presentation will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa's website within approximately 48 hours after the event.

About Kiniksa

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio assets, ARCALYST[®], KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST[®] is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts![®]

Kiniksa Investor and Media Contact

Rachel Frank
(339) 970-9437
rfrank@kiniksa.com